$36.46
-0.03-0.08%
Last update: Nov 11, 4:18 PM
Pacira BioSciences Inc
PCRXNASDAQ
Pacira BioSciences rose 51.2% from $24.12 to $36.46, ahead of the S&P 500's +9.8%. Its worst day was Aug 5 (−10.0%), and its low came Jan 16 at $19.16.
Nov 11, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Pacira BioSciences closed at its lowest level of the year, 20.6% below where the year started.
−7.2% · S&P 500 −0.1%
EPS of $0.57 missed the $0.78 estimate on $196.9M revenue (est. $200.0M); FY revenue guidance of $745.0M–$770.0M against the $766.9M consensus.
Story events cover the past 12 months · Times ET
−3.0% · S&P 500 −0.5%
EPS of $0.60 beat the $0.52 estimate on $177.4M revenue (est. $173.9M); FY revenue guidance of $745.0M–$770.0M against the $761.5M consensus.
−4.1% · S&P 500 +0.3%
EPS of $0.73 beat the $0.57 estimate on $192.4M revenue (est. $190.9M); FY revenue guidance of $735.0M–$760.0M against the $767.8M consensus.
−10.0%, the year's worst day · S&P 500 −0.2%
Pacira BioSciences shares rose 44.4%, while the S&P 500 fell 0.4%.
+44.4%, the year's best day, on 29M shares, the year's heaviest volume · S&P 500 −0.4%
Where it ended: a close of $36.46 on Nov 11, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $0.78, revenue est. $201.9M).
Nothing in the past 12 months.
All PCRX dividend historyReplay the year: the line draws itself and stops at each of the 5 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PCRX and SPY from Benzinga historical bars. Not investment advice.
